Trial Profile
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ELND 005 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms Harmony AD; Harmony-AD; HarmonyAD
- Sponsors Transition Therapeutics
- 10 Nov 2015 According to a Transition Therapeutics media release, data from this trial was presented at the Clinical Trials in Alzheimer's Disease (CTAD) meeting.
- 28 Oct 2015 Data from this trial will be presented at the Clinical Trials in Alzheimer's Disease (CTAD) 2015, according to a Transition Therapeutics media release.
- 15 Oct 2015 Data of this trial will also be presented at the Clinical Trials in Alzheimer's Disease meeting in Barcelona, as per Transition Therapeutics media release.